AstraZeneca’s Q4 results were disappointing, both from a sales growth and profitability perspective. While Oncology and CVRM (to some extent) remain the key growth drivers, growing competition is concerning. Moreover, with the 2019-nCoV scare, near-term business visibility has hit a low. However, the group still has one of the largest oncology pipelines in our coverage and is awaiting/applying for/in major new indications/geographies in Oncology and even CVRM, which should give a push t
21 Feb 2020
Q4 (growth) hits a wall; 2019-nCoV overshadows the near term
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 (growth) hits a wall; 2019-nCoV overshadows the near term
AstraZeneca PLC (AZN:LON) | 11,349 9533.2 0.7% | Mkt Cap: 175,936m
- Published:
21 Feb 2020 -
Author:
Surbhit Gupta -
Pages:
5
AstraZeneca’s Q4 results were disappointing, both from a sales growth and profitability perspective. While Oncology and CVRM (to some extent) remain the key growth drivers, growing competition is concerning. Moreover, with the 2019-nCoV scare, near-term business visibility has hit a low. However, the group still has one of the largest oncology pipelines in our coverage and is awaiting/applying for/in major new indications/geographies in Oncology and even CVRM, which should give a push t